• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POS AM filed by Pasithea Therapeutics Corp.

    1/26/26 8:00:16 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KTTA alert in real time by email
    POS AM 1 ea027402501-posam_pasithea.htm POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3

     

    As filed with the Securities and Exchange Commission on January 26, 2026  

    Registration No. 333-271010

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    POST-EFFECTIVE AMENDMENT NO. 1

    TO

    FORM S-3 REGISTRATION STATEMENT NO. 333-271010

     

    UNDER

    THE SECURITIES ACT OF 1933

     

    PASITHEA THERAPEUTICS CORP.

    (Exact name of registrant as specified in its charter)

     

    Delaware   85-1591963

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

     

    1111 Lincoln Road, Suite 500

    Miami Beach, Florida 33139

    (786) 977-3380

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    Tiago Reis Marques

    Chief Executive Officer

    Pasithea Therapeutics Corp.

    1111 Lincoln Road, Suite 500

    Miami Beach, Florida 33139

    (786) 977-3380

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    With copies to:

     

    James O’Grady, Esq.

    Lowenstein Sandler LLP

    1251 Avenue of the Americas

    New York, New York 10020

    Telephone: (212) 262-6700

     

    Approximate date of commencement of proposed sale to the public: Not applicable. Removal from registration of securities that were not sold pursuant to the above referenced registration statement.

     

    If the only securities being registered on this form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: ☐ 

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: ☐

     

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

     

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
        Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

    DEREGISTRATION OF SECURITIES

     

    Pasithea Therapeutics Corp., a Delaware corporation (the “Registrant”), is filing this Post-Effective Amendment No. 1 (the “Amendment”) to the Registration Statement on Form S-3 (File No. 333-271010) filed by the Registrant with the Securities and Exchange Commission (“SEC”) on March 30, 2023 and declared effective by the SEC on April 19, 2023 (the “Registration Statement”), to deregister any and all securities of the Registrant registered but unsold or otherwise unissued under the Registration Statement as of the date hereof.

     

    The Registration Statement pertains to the registration of an indeterminate amount of (i) the Registrant’s common stock, (ii) the Registrant’s preferred stock, (iii) warrants, (iv) subscription rights and (v) units, or any combination of the foregoing, having an aggregate offering price not to exceed $15,000,000.

     

    Any and all offerings of the Registrant’s securities pursuant to the Registration Statement have been terminated. Accordingly, the Registrant hereby terminates the effectiveness of the Registration Statement. In addition, in accordance with undertakings made by the Registrant in the Registration Statement to remove from registration, by means of a post-effective amendment, any securities being registered which remain unsold at the termination of the offering, the Registrant hereby removes from registration all securities registered under the Registration Statement that remain unsold under the Registration Statement as of the date hereof. The Registration Statement is hereby amended, as appropriate, to reflect the deregistration of such securities.

     

    1

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all the requirements for filing on Form S-3 and has duly caused this Post-Effective Amendment No. 1 to the Registration Statement on Form S-3 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Miami Beach, State of Florida, on January 26, 2026.

     

      PASITHEA THERAPEUTICS CORP.
         
      By:

    /s/ Tiago Reis Marques

      Name:  Dr. Tiago Reis Marques
      Title: Chief Executive Officer

     

    No other person is required to sign this Post-Effective Amendment No. 1 to the Registration Statement in reliance on Rule 478 of the Securities Act of 1933, as amended. 

     

    2

     

    Get the next $KTTA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KTTA

    DatePrice TargetRatingAnalyst
    12/14/2021$3.25Buy
    EF Hutton
    More analyst ratings

    $KTTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Steinman Lawrence bought $100,000 worth of shares (133,333 units at $0.75), increasing direct ownership by 201% to 199,691 units (SEC Form 4)

    4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)

    12/1/25 9:07:14 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Marques Tiago bought $25,000 worth of shares (33,333 units at $0.75), increasing direct ownership by 83% to 73,334 units (SEC Form 4)

    4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)

    12/1/25 8:56:56 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Dumesnil Simon bought $25,000 worth of shares (33,333 units at $0.75), increasing direct ownership by 1,333% to 35,833 units (SEC Form 4)

    4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)

    12/1/25 8:54:08 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KTTA
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Pasithea Therapeutics Corp.

    SCHEDULE 13G - Pasithea Therapeutics Corp. (0001841330) (Subject)

    2/12/26 9:01:43 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Pasithea Therapeutics Corp.

    S-8 - Pasithea Therapeutics Corp. (0001841330) (Filer)

    1/30/26 4:15:51 PM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pasithea Therapeutics Corp. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Pasithea Therapeutics Corp. (0001841330) (Filer)

    1/28/26 4:15:46 PM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KTTA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines

    MIAMI, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation oral macrocyclic MEK inhibitor for the treatment of neurofibromatosis type 1 associated plexiform neurofibromas (NF1-PN), today provided updated timelines on its ongoing clinical trials in advanced cancer and adult NF1-PN patients. Ongoing Phase 1/1b clinical trial in adult patients with NF1-PN (NCT06961565): Pasithea has completed enrollment of 12 patients through the first 4 dose cohorts (4, 8, 12 and 18 mg tablets) in Part A of the study.    The Company plans to present data in the second half of

    1/13/26 7:01:00 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock

    Extends cash runway through at least the first half of 2028Led by healthcare-dedicated investors, including Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners and Squadron Capital Management MIAMI, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. ("Pasithea" or the "Company") (NASDAQ:KTTA, KTTAW)), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), today announced the closing of its previously announced public offering of 80,000,000 shares of the Company's common

    12/2/25 7:00:00 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock

    Extends cash runway through at least the first half of 2028Led by Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners, and Squadron Capital Management MIAMI, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. ("Pasithea" or the "Company") (NASDAQ:KTTA, KTTAW)), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), today announced the pricing of a public offering of 80,000,000 shares of the Company's common stock (or pre-funded warrants in lieu thereof) at an offering pr

    11/28/25 9:20:00 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KTTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Steinman Lawrence bought $100,000 worth of shares (133,333 units at $0.75), increasing direct ownership by 201% to 199,691 units (SEC Form 4)

    4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)

    12/1/25 9:07:14 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Schneiderman Daniel H was granted 26,667 shares (SEC Form 4)

    4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)

    12/1/25 9:04:30 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Marques Tiago bought $25,000 worth of shares (33,333 units at $0.75), increasing direct ownership by 83% to 73,334 units (SEC Form 4)

    4 - Pasithea Therapeutics Corp. (0001841330) (Issuer)

    12/1/25 8:56:56 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KTTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    EF Hutton initiated coverage on Pasithea Therapeutics with a new price target

    EF Hutton initiated coverage of Pasithea Therapeutics with a rating of Buy and set a new price target of $3.25

    12/14/21 8:32:07 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KTTA
    Leadership Updates

    Live Leadership Updates

    View All

    Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board

    MIAMI, June 11, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced the appointment of Dr. James Lee to its scientific advisory board (SAB) to help guide development of PAS-004 for the treatment of ETS2 pathway inflammatory diseases including inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, primary sclerosing cholangitis and ankylosing spondylitis. Dr. Lee is the lead author on a 2024 Nature publication that identified ETS2 as a central regulator of macrophage-driven inflammation in IBD and other indic

    6/11/25 7:02:00 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board

    MIAMI, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other indications, announced today that Rebecca Brown, M.D., Ph.D. has been appointed as a member of the Company's Scientific Advisory Board. Dr. Brown is currently Director of the Neurofibromatosis Clinic at The Mount Sinai Hospital and Assistant Professor in the Department of Neurology (Division of Neuro-Oncology), Internal Medicine, and Neurosurgery at the institution. Dr. Brown will contribute scientific insights

    9/3/24 8:02:00 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pasithea Therapeutics Announces Results from 2023 Annual Meeting

    SOUTH SAN FRANCISCO, Calif. and MIAMI, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. ("Pasithea" or the "Company") (NASDAQ:KTTA), today announced that it held its annual meeting of stockholders (the "Annual Meeting") on December 19, 2023. Over 70% of the Company's shares of common stock were represented at the Annual Meeting. More than 95% of shares voted were cast "for" the election of directors (Proposal 1), and over 85% "for" Proposals 2, 3 and 6 (collectively, the "Approved Proposals"). The Approved Proposals related to the following matters: appointment of the Company's proposed slate of directors;-  Dr. Tiago Reis Marques;-  Prof. Larry Steinman;-  Simon Dume

    12/19/23 5:19:00 PM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KTTA
    Financials

    Live finance-specific insights

    View All

    Pasithea Therapeutics Acquires AlloMek Therapeutics

    -- Expands CNS Product Portfolio with Addition of CIP-137401, a Macrocyclic, Next-Generation MEK Inhibitor -- Plans to File IND Application with the FDA to Enter the Clinic in 2H 2023 -- Plans to Initiate a Phase 1 Clinical Trial in the U.S. for Neurofibromatosis Type 1 (NF1) -- Management to Host an Investor Webcast Today at 9 a.m. ET MIAMI BEACH, Fla., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a biotechnology company focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders, today announced that it acquired AlloMek Therapeutics, LLC ("AlloMek"), a privately-he

    10/12/22 8:00:00 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pasithea Therapeutics Acquires Alpha-5 Integrin, LLC

    - Alpha-5 is a potentially first-in-class monoclonal antibody for the treatment of amyotrophic lateral sclerosis (ALS) and other neurological diseases -- Expands pipeline across Pasithea's core therapeutic areas to drive enhanced growth -- Closing consideration of 3.26 million shares of Pasithea common stock -- Pasithea to hold a webcast on June 22 at 9 a.m. ET to discuss the transaction - MIAMI BEACH, Fla., June 22, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), today announced its acquisition of Alpha-5 integrin, LLC ("Alpha-5"), a privately-held preclinical-stage company developing a monoclonal antibody (mAbs) for the treatment of am

    6/22/22 8:00:00 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KTTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Pasithea Therapeutics Corp.

    SC 13G - Pasithea Therapeutics Corp. (0001841330) (Subject)

    11/14/24 3:32:41 PM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Pasithea Therapeutics Corp. (Amendment)

    SC 13G/A - Pasithea Therapeutics Corp. (0001841330) (Subject)

    1/13/23 8:02:14 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Pasithea Therapeutics Corp. (Amendment)

    SC 13D/A - Pasithea Therapeutics Corp. (0001841330) (Subject)

    1/10/23 3:55:25 PM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care